Understanding pediatric ED readiness: Quartiles, disparities, and cost
Nathan Kuppermann, MD, MPH, explains the different quartiles of the pediatric emergency department readiness scale, and why the top tier is so crucial for pediatric patients.
FDA approves remestemcel-L-rknd to treat steroid-refractory acute graft-versus-host disease
With the federal agency's decision, remestemcel-L-rknd has become the first FDA-approved mesenchymal stromal cell therapy.
COVID-19 Roundtable: Considering off label therapies
This week, our experts weigh in on treatments not specifically indicated for COVID-19 treatment, including metformin, and concerns around using medications in this way.
2-week-old girl with lesions on her lips, cheeks, and nasolabial folds
Can you diagnose this healthy, 8.2-lb girl with lesions primarily on her lower lip but also her upper lip, cheeks, and nasolabial folds?
Contemporary Pediatrics’ top 3 FDA approvals of 2024
From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.
Johnson & Johnson submits application for golimumab to treat pediatric ulcerative colitis patients
Currently, golimumab is approved in adults with moderately to severely active ulcerative colitis.
Screening for diabetes in primary care and CGM, AID advice for providers
Greg Forlenza, MD, offers practical advise for primary care providers regarding continuous glucose monitors and automatic insulin delivery systems.
FDA accepts BLA for clesrovimab to prevent RSV in infants' first RSV season
The federal agency has set a target action date of June 10, 2025 for potential approval.
FDA approves nemolizumab to treat atopic dermatitis in patients 12 years and up
According to Galderma, approval is based on positive results from the phase 3 ARCADIA clinical trial program.
FDA approves tapinarof cream, 1% for atopic dermatitis patients 2 years and up
"I really hope this becomes a first-line agent that people are comfortable prescribing whether they are in dermatology, pediatric dermatology, or primary care."
Keeping up with type 1 diabetes technology changes in primary care
A discussion of the evolving landscape of diabetes technology and its implications for primary care providers.
Pediatric RSV vaccine trial enrollment on hold in US, VRBPAC says
The halt follows a severe respiratory disease safety signal observed in a July 2024 phase 1 trial of Moderna's mRNA-1345 and mRNA-1365 vaccine candidates.
COVID-19 Therapy Roundtable: focusing on inpatient care
In this episode, the panel discusses therapies and care around inpatients including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir.
Leniolisib: positive phase 3 data in children aged 4 to 11 years with APDS
Pharming Group N.V. plans to include these findings in worldwide regulatory filings in 2025.
Using a smartphone application to screen for neonatal jaundice
A good correlation and statistical agreement with total serum bilirubin was observed in a study of a new smartphone-based machine learning app, leaving it a potential neonatal jaundice screening tool.
Upadacitinib effective in treating atopic dermatitis through 76 weeks
In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).
J&J submits applications for guselkumab to treat plaque psoriasis, jPsA in children
The submission to treat PsO is for children aged 6 years and up while the jPsA submission is to treat children aged 5 years and older.
A preview of the November/December issue of Contemporary Pediatrics
Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the final Contemporary Pediatrics journal of the year.
Zelicapavir demonstrates antiviral effect in phase 2 RSV study
Zelicapavir demonstrated a favorable safety profile and was well-tolerated. The N-protein inhibitor has been granted Fast Track Designation by the FDA.
Survey: titrating trofinetide improves tolerability among Rett syndrome patients
Respondents reported decreased diarrhea severity, improved patient quality of life, and decreased treatment discontinuation among patients with Rett syndrome treated with trofinetide.
Weekly review: COVID-19 roundtable, upadacitinib data for AD, and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Asthma associated with memory, executive function difficulty in children
Results demonstrated that those with earlier asthma onset had slower development of episodic memory.
Study links depression to increased menstrual pain
A new study highlights how depression may drive dysmenorrhea through shared genetic pathways, emphasizing the need for mental health screening and holistic care for women.
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
In our latest roundtable series, we cover different therapies around COVID-19 treatment and prevention.
Fremanezumab for episodic migraine prevention demonstrates positive phase 3 data
Both monthly migraine days and headache days were reduced vs placebo in patients aged 6 to 17 years.
FDA grants Rare Pediatric Disease to 101-PGC-005 for systemic juvenile idiopathic arthritis
101-PGC-005 is Type IA prodrug of dexamethasone that targets CD206+ macrophages.
Saol Therapeutics submits NDA for SL1009 to treat Pyruvate Dehydrogenase Complex Deficiency
If approved, SL1009 has the potential to be the first approved medication for PDCD, and would be available as an oral solution.
Weekly review: Vaccine coverage, exemptions, and mRNA reactions
Cultivating gratitude boosts family wellbeing, experts say
Practicing gratitude boosts wellbeing, improves sleep, and reduces stress. Parents can foster it daily by modeling gratitude, helping others, and reflecting on positives.
No unexpected reactions present among mRNA COVID-19 vaccination in kids
The most common reactions reported were the following: irritability or fussiness (30.1%), local reactions (21.1%) and fever (13.8%).
